" class="no-js "lang="en-US"> Prolifagen Therapeutics - Medtech Alert
Wednesday, April 16, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Prolifagen Therapeutics | Pharmtech Focus

Prolifagen Therapeutics

About Prolifagen Therapeutics

Prolifagen Therapeutics

Founded in 2016, Prolifagen is an early-stage biotech startup whose mission is to prevent the development of heart failure in patients with large myocardial infarcts.  It currently has a microRNA therapeutic, PRO-302, that has been successful in inducing regeneration of heart muscle during the first month after infarct in mouse and pig models. It plans to begin clinical studies soon.

Related Story

Appointments

 Prolifagen Therapeutics Appoints M. Alexander Shaw

Prolifagen Therapeutics Appoints M. Alexander Shaw, PhD, as Chief Executive Officer

September 14 2022

Prolifagen Therapeutics, a biotech startup developing medicines for cardiac regeneration, has appointed M. Alexander Shaw, PhD, […]